Literature DB >> 7383109

Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure.

M Packer, J Meller, N Medina, R Gorlin, M V Herman.   

Abstract

To examine the importance of left ventricular chamber size in determing the response to vasodilator therapy, we performed echocardiography in 40 patients with chronic refractory heart failure before they were treated with oral hydralazine. The left ventricular end-diastolic dimension (LVEDD) correlated significantly with the per cent change in stroke volume (r = 0.77), left ventricular filling pressure (r = -0.68), and stroke work index (r = 0.87) during short-term drug administration. After 14 to 21 days of maintenance therapy, 15 of 24 patients with an LVEDD greater than or equal to 60 mm were improved, and one was worse; mean blood urea nitrogen decreased from 45.6 to 30.6 mg per deciliter in the 21 patients in this group who completed the study (16.3 to 10.9 mmol per liter) (P less than 0.001). In contrast, only two of 16 patients with an LVEDD less than 60 mm improved, whereas 10 showed clinical deterioration; blood urea nitrogen increased from 49.3 to 64.2 mg per deciliter in the 13 patients in this group who completed the study (17.6 to 22.9 mmol per liter) (P less than 0.01). These findings indicate that left ventricular chamber size is an important factor in the response to hydralazine in patients with severe chronic heart failure.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7383109     DOI: 10.1056/NEJM198007313030503

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  8 in total

Review 1.  Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.

Authors:  M Packer
Journal:  Drugs       Date:  1982-07       Impact factor: 9.546

2.  Mathematical model of cardiovascular mechanics for diagnostic analysis and treatment of heart failure: Part 2. Analysis of vasodilator therapy and planning of optimal drug therapy.

Authors:  H Tsuruta; T Sato; N Ikeda
Journal:  Med Biol Eng Comput       Date:  1994-01       Impact factor: 2.602

Review 3.  The role of vasodilator therapy in the treatment of severe chronic heart failure.

Authors:  M Packer
Journal:  Drugs       Date:  1986       Impact factor: 9.546

4.  Effect of afterload reduction in patients with ventricular and physiological pacing.

Authors:  M Been; D P de Bono; H C Miller; W S Hillis
Journal:  Br Heart J       Date:  1984-03

5.  Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction.

Authors:  D J Fitzgerald; W G O'Callaghan; K O'Malley; J Horgan; E O'Brien
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  Does digitalis work in chronic heart failure? The end of a 200-year-old controversy.

Authors:  M Packer
Journal:  Cardiovasc Drugs Ther       Date:  1989-01       Impact factor: 3.727

Review 7.  Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.

Authors:  W J Remme
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 8.  Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.

Authors:  J P Mulrow; M H Crawford
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.